Stock 6823 RION CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Rion Co., Ltd.

Equities

6823

JP3969700008

Market Closed - Japan Exchange
Other stock markets
 07:00:00 17/05/2024 BST 		5-day change 1st Jan Change
3,010 JPY -0.17% Intraday chart for Rion Co., Ltd. -0.99% +23.41%
02-06 Rion Co., Ltd. Provides Commemorative Dividend Guidance for Fiscal Year Ending March 31, 2024 CI
02-06 Rion Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.

Weaknesses

  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
RION CO., LTD. Stock Rion Co., Ltd.
+23.41% 238M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.43% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
+4.30% 114B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.09% 68.29B
A
DEXCOM, INC. Stock DexCom, Inc.
+5.86% 52.24B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.15% 44.3B
B-
HOYA CORPORATION Stock Hoya Corporation
+7.52% 42.73B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+25.54% 32.52B
B
TERUMO CORPORATION Stock Terumo Corporation
+17.85% 26.02B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+1.00% 25.91B
A-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6823 Stock
  4. Ratings Rion Co., Ltd.